Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT04884906
Phase
PHASE2
Status
Unknown

Conditions

  • Locally Advanced Cervical Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — BIOLOGICAL
    200mg/m2, iv, d1, Q3W, a total of 6 cycles
  • radiotherapy — RADIATION
    1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
  • Albumin Paclitaxel — DRUG
    260mg/m2, iv, d1, Q3W, a total of 6 cycles
  • Cisplatin — DRUG
    80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles

Study Details

To evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer

Key Dates

Start date
Nov 1, 2020
Status verified
May 2021
Primary completion
Nov 1, 2022
Completion
Nov 1, 2024

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab combined with radiotherapy and chemotherapy

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 2 year ]

Central Contacts

  • Chen

Related Studies